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ABSTRACT 
Rheumatoid Arthritis (RA) pharmacotherapy may impact mental health (MH) outcomes by 
improving pain and stiffness; and potentially via targeting inflammatory processes common to RA 
and depression. The objectives of this review were to i) ascertain the frequency of MH assessment 
in RA pharmacotherapy trials; ii) quantify the efficacy of RA pharmacotherapy efficacy on MH 
outcomes; iii) explore the clinical and demographic factors related to MH outcomes. 
CENTRAL, PsychINFO, Web of Science, Medline, Embase and CINAHL were systematically 
searched from inception to March 2017 for randomised trials of disease-modifying anti-rheumatic 
drugs (DMARDs) in adult RA patients. The primary outcome was MH; self-reported physical health 
was extracted as a secondary outcome. Pairwise meta-analysis (PMA) created pooled effect sizes 
and 95%CIs for comparisons of all treatments versus comparators (active or placebo). Network 
meta-analysis (NMA) provided effect size estimates of targeted biologic DMARDs (bDMARDs) 
versus conventional synthetic DMARDs (csDMARDs) using indirect comparisons of different 
treatment modalities. 
71 eligible studies were identified. 57 studies were included in the PMA, representing 23,535 
patients. bDMARDs showed small effects on MH (standardised mean difference (SMD) versus 
csDMARDs = 0.19 to 0.30), and moderate effects on self-reported physical health (SMD versus 
csDMARDs = 0.46 to 0.50), with NMA determining no significant differences in effectiveness 
between bDMARD mode of action on either outcome.  
Effective pharmacotherapy alone is unlikely to substantially improve MH outcomes for most RA 
patients. Integrated MH care provided within routine clinical practice is essential to optimise mental 
and physical health outcomes.  
 
 
 
 
DECLARATION OF INTERESTS 
None 
 
Keywords: anti-tnf, DMARDs (biologic), rheumatoid arthritis, psychology, treatment 
3 
 
INTRODUCTION 
Rheumatoid Arthritis (RA) is an autoimmune disease with a prevalence of 0.5-1.0% in adults. 
[1] RA causes swelling and pain of the joints (mainly hands, wrists and feet) reducing 
functional ability, which can substantially impact both physical and mental quality-of-life (QoL; 
[2]). Mental health (MH) disorders are highly prevalent; approximately 17% of RA patients 
have depressive disorder according to diagnostic interview [3] and 25.1% of rheumatology 
outpatients screen positive for anxiety disorder. [4] These estimates are substantially higher 
than for the general population, where depression prevalence estimates are typically around 
5%. [5]  Poor MH is associated with numerous deleterious outcomes in RA; increased risk of 
mortality, [6] work disability, [7] worsened disease activity and physical function, [8–10] higher 
pain and [11] fatigue. [12]  
There is increasing evidence suggesting common inflammatory pathways between RA and 
depression. Specifically, inflammatory cytokines including tumour necrosis factor alpha (TNF-
α) and interleukin-6 (IL-6) can be elevated in people with depressive disorder [13] and recent 
evidence suggests that therapies used in RA targeting TNF-α inhibitors may improve MH 
outcomes in depressed patients with high levels of inflammation, [14] and with chronic physical 
illness. [15]   
RA management has evolved in the last 25 years, with earlier diagnosis, and earlier, more 
aggressive treatment. [16] The “treat to target” framework emphasises the desired goal of 
reaching a state of remission, switching medications until this target has been achieved. 
[17,18] Initial treatment typically involves conventional synthetic disease-modifying anti-
rheumatic drugs (csDMARDs), usually methotrexate. In the UK, more expensive targeted 
biologic DMARDS (bDMARDs) are reserved for those with insufficient response to two 
csDMARDs. [19] For the purposes of this review, we use the term bDMARDs to encompass 
both targeted biologic and Janis kinase inhibitor (JAK) treatments. Whilst there has been 
evident improvements in radiographic outcomes and inflammation, impact on physical function 
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and QoL is less pronounced. [20,21] The limited impact on QoL is worrying given that 
psychosocial wellbeing and social function are of key importance to patients. [15] 
As low mood is highly prevalent in RA, [3]  and psychosocial wellbeing is important to patients, 
[22] it might be expected that MH is commonly assessed as an outcome in RA clinical trials. 
However, a 2009 systematic review found that MH outcomes were reported in 4% of RA 
clinical studies, [23] increasing to 22% with a broader conceptualisation of mood including MH 
components of QoL using questionnaires such as the Medical Outcome Survey 36-item Short 
Form (SF36; [24]).   
The aim of this study was to systematically review the evidence around the efficacy of 
pharmacotherapy on improving MH outcomes in RA. The objectives were to: 1) identify the 
frequency with which MH outcomes are measured and reported in RA pharmacotherapy trials; 
2) quantify the impact of bDMARDs on MH outcomes, comparing against self-reported 
physical health; and 3) investigate factors that may moderate RA pharmacological treatment 
efficacy for MH outcomes, such as treatment mode of action, patient demographic, and clinical 
characteristics.  
METHODS 
Identification of trials 
A protocol and data extraction form were developed in accordance with the Preferred 
Reporting Items for Systematic reviews and Meta-Analyses (PRISMA; [25]) statement 
(appendix 1). We searched the Cochrane Central Register of Controlled Trials (CENTRAL), 
PsychINFO, Medline, Embase, Web of Science and CINAHL from inception to March 2017. 
Search terms are available in the protocol, provided in appendix 2.  We also screened 
reference lists of reviews and ClinicalTrials.gov for trials still in progress. Titles were screened 
for relevance, followed by abstracts and full-texts to assess eligibility for inclusion. This 
screening procedure was conducted by reviewer FM, with reviewer ER following the same 
procedure for 10% (460/4604) of identified articles.  
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Selection criteria 
Types of patient 
Studies reporting data from adult patients aged >18 years with RA were included. Studies 
spanning several disease groups were only eligible if results from RA patients were reported 
separately. 
Study design and treatment types 
Randomised controlled trials (RCTs) of bDMARD pharmacological treatments for managing 
RA, including drugs in use in clinical practice at the time of study and new drugs under 
investigation, were eligible. Generic pain relief medication or alternative and complementary 
therapies such as acupuncture or collagen were excluded. Trials including active comparators 
(bDMARD vs. bDMARD), placebo control groups (bDMARD vs. placebo) or usual care control 
groups (bDMARD vs. csDMARD) were included, as were multi-arm trials (bDMARD vs. 
bDMARD vs. csDMARD). For cross-over trials, data were extracted from the first period only, 
to avoid potential carryover effects. Pragmatic trials, with patients shifting between treatment 
modalities and dosages according to treatment response were included in a narrative 
synthesis.   
Outcomes 
Our primary outcome of interest was MH, including both traditional depression and anxiety 
questionnaires and generic measures of QoL that include MH subscales. Data from these 
questionnaires were included if they were reported from MH subscales separately from overall 
quality-of-life or disability scores.  
Based on previous systematic review evidence, [23] we anticipated that the SF36 would be 
the most commonly-used questionnaire. If data were reported from more than one MH 
questionnaire, data from the SF36 were prioritised for inclusion in meta-analysis to reduce 
heterogeneity and aid interpretation. The SF36 has eight domains assessing various aspects 
of mental and physical well-being: physical function (PF); role physical (RP); global health 
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(GH); bodily pain (BP); vitality (V); social function (SF); role emotional (RE); and mental health 
(MH). [26] These domains can be combined to form two higher-order summary scores: 
Physical Component Summary (PCS); and Mental Component Summary (MCS). The PCS is 
formed by positively weighting the physical domains (PF, RP, GH, BP) and negatively 
weighting the mental domains (V, SF, RE, MH) and the MCS is calculated by positively 
weighting the mental domains and negatively weighting the physical domains. The PCS and 
MCS summary scores are inter-related, [27] yet provide an indicator of the impact of treatment 
on physical outcomes in comparison to mental outcomes, with higher scores indicating 
improved mental/physical QoL. PCS scores were considered secondary outcome data, to 
allow comparison between mental QoL and physical QoL outcomes following RA treatment. 
Data extraction 
Data were extracted from all eligible papers (N=71) by two reviewers (FM and ER) 
independently, to minimise human error in reporting results (appendix 3). In the case of 
incomplete reporting of data, we searched ClinicalTrials.gov, accessed company-specific 
registries, contacted authors directly, and made data requests to funding bodies as necessary.  
Risk of Bias 
A key assessment of the quality of the information provided by a trial is the potential for bias 
in the treatment effect estimate. Risk of bias of included trials was assessed by 2 reviewers 
(FM/ER) using the Cochrane tool. [28] This assessed random sequence generation, allocation 
concealment, participant, personnel and outcome assessor blinding, completeness of 
outcome data, and selective reporting. Where necessary, this data was obtained from “parent” 
primary outcome papers, where more detailed methodological information is included.  
The quality of each outcome was assessed using the Grading of Recommendations 
Assessment, Development, and Evaluation (GRADE) system. A rating of high, moderate, low 
or very low was given to each outcome (MCS and PCS), based on assessment of risk of bias, 
inconsistency (between estimated effect sizes across studies and estimated I2 heterogeneity), 
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indirectness (applicability of study to the review aim), imprecision, and risk of publication bias 
(appendix 4).  
Statistical methods 
Standardised mean difference (SMD) effect sizes were calculated for each comparison using 
group means and standard deviations (SDs). The SMD indicates the size of the treatment 
effect relative to the observed variability in the outcome and can be interpreted as the between 
group difference in SD units; where an SMD of .5 indicates half a SD difference. A rule of 
thumb is that SMDs of .2, .5 and .8 are interpreted as small, medium, and large effects, 
respectively [29]. Where multiple doses of the same drug were tested, the most commonly 
used dosage, or dosage most reflecting clinical practice was included in the pooled meta-
analysis. Where dose-finding studies of new drugs used a range of doses, the mean scores 
across dosages was taken. Endpoint means were prioritised, however mean change scores 
were included where endpoint scores were unavailable. If no mean scores or SDs were 
available after accessing ClinicalTrials.gov, or contacting authors and funding bodies, effect 
sizes were calculated using any available statistical estimates including t-scores, 95% 
confidence intervals, and p-values. [30] Missing SD data were imputed by calculating the 
mean SD from data available from other studies using the same outcome, drug and dosage 
at the same time-point.  
The analysis involved random-effects pairwise meta-analysis (PMA), due to expected 
heterogeneity, including all studies regardless of comparator using Stata v14. Subgroup 
analyses compared active treatment separately with (no treatment) placebo and with 
csDMARD controls. Statistical heterogeneity in the between study treatment effects was 
assessed using I2 , with scores of 25%, 50% and 75% representing low, moderate and high 
heterogeneity respectively. [31] The pooled treatment effect estimated may not be trustworthy 
when heterogeneity is high. Additionally, meta-regression was used to investigate between 
study differences in design and patient characteristics that might account for variability in 
between study treatment effects. Study sample size, age, proportion female, disease duration, 
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baseline mood, baseline disease activity, follow-up time in weeks, rheumatoid factor (RF) 
status, recruitment year, and availability of data were entered as a bivariate exploration in 
studies of bDMARDs vs csDMARDs. A significant difference between analyses was 
established when confidence intervals did not overlap.  
Studies examining bDMARDs vs. csDMARDs were used in network meta-analysis (NMA) of 
targeted therapies by mode of action. NMA is an extension of traditional PMA to multiple 
treatment comparisons, which allows indirect comparisons to be made between different 
treatment types. [32] For example, if etanercept and abatacept have both been compared 
directly to MTX in different trials, the relative effectiveness of etanercept versus abatacept can 
be estimated indirectly. This method also has the benefit of combining direct and indirect 
comparisons to provide a more precise (i.e. smaller standard errors) estimate of effect size. 
[32]   
Since the NMA grouped treatment by mode of action, it was necessary to exclude studies 
comparing bDMARDs with the same mode of action without a csDMARD or placebo control 
arm. Typically, such studies concerned a bDMARD biosimilar. Effect sizes were presented as 
pooled SMD and 95% CIs. Direct and indirect estimates of effect size were compared for 
bDMARD subcategories where direct comparisons were available, and comparison-adjusted 
funnel plots were created to indicate differences in effect sizes between small and large 
studies. Targeted treatments were ranked based on the estimated probability of each targeted 
treatment being most effective for MCS and PCS outcomes, which was estimated using 
surface under the cumulative ranking curve (SUCRA). SUCRAs combine the estimated 
probabilities (derived from the NMA) that each treatment is the first best, second best, and so 
on for all possible ranks (provided in web appendix 4). Higher SUCRA values indicate greater 
likelihood of a given treatment being the most efficacious, such that where the SUCRA is one 
the treatment is certain to be the best, and where it is zero is certain to be the worst.  
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RESULTS 
Search results and included participants 
A total of 71 studies, involving 34,796 participants, were identified (figure 1/table1). Full 
references for these studies are provided in appendix 6. The mean age of patients ranged 
from 47 to 57.5 years, 78.6% female, and the mean disease duration ranged between 0.1 and 
12.3 years.  The mean baseline MCS scores was 42.2 and the mean baseline DAS-28 was 
6.2. The studies considered 16 bDMARDs: anti-TNFs (adalimumab, certolizumab, etanercept, 
golimumab, infliximab); B-cell inhibitors (rituximab, SBI-087); T-cell inhibitors (abatacept); anti-
IL6 (clazakizumab; sarilumab; sirukumab; tocilizumab) and Janus Kinase inhibitors (baricitinib, 
decernotinib, fostamitinib, tofacitinib).  
Objective 1: The frequency of MH outcome measurement 
Of the 71 eligible studies, with evidence of mood having been measured in either an abstract, 
methods, or as a list of outcomes on ClinicalTrials.gov, only 36 (50.7%) reported MH data in 
either publications, supplementary material, or open online data summary reports. Attempts 
were made to contact authors and funders of 32 of the remaining 35 studies with insufficient 
information available (3 papers did not have contact information or funding information 
available); only 12 (36.4%) of these contact attempts resulted in receipt of the necessary data. 
Of the remaining 23 where no data were available, imputation of the missing information (e.g. 
SD of the outcome) was possible for 12 studies (allowing inclusion in the meta-analysis), 4 
reported some data which were added to the narrative synthesis (appendix 7), and 7 were not 
able to be included in any outcome assessment. A total of 57 papers were included in the 
PMA and 54 in the NMA. The three studies omitted from the NMA were head-to-head trials of 
targeted therapies in the same class. 
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Table 1. Study characteristics. 
Study ID Analysis 
Inclusion 
Interventions Year Patient N Female 
N (%) 
Mean 
Age, (SD) 
Mean 
disease 
duration 
(SD) 
Follow-
up 
(weeks) 
Missing 
data 
Mood 
measurement 
Baselin
e 
mood, 
mean 
(SD) 
ADACTA Meta-analysis Tocilizumab (8mg/kg 
q4w) vs adalimumab 
(40mg eow) 
2010-2011 325 262 
(80.6) 
53.4 
(12.7) 
6.8 24 LOCF SF36 - 
AIM Meta-analysis Placebo (+MTX) vs 
abatacept (10mg/kg 
q4w) 
 652 516 
(79.1) 
51.0 
(12.7) 
8.7 (7.2) 52 LOCF SF36 41.3 
(11.3) 
Alemao 2014 Meta-analysis MTX vs 
clazakizumab (25-
200mg q4w)        
MTX vs adalimumab 
(40mg eow) 
- 418 - - - 24 - SF36 - 
AMPLE Meta-analysis Abatacept 
(125mg/wk) vs 
adalimumab (40mg 
eow) 
- 646 529 
(81.9) 
51.2 
(12.7) 
1.8 (1.4) 104 Excluded SF36 43.5 
(11.5) 
APPEAL Meta-analysis DMARD+MTX   vs 
etanercept 
(50mg/wk) 
2007-2009 300 271 
(90.3) 
48.5 
(11.7) 
6.2 (7.9) 16 LOCF SF36   42.7   
ATTAIN Meta-analysis Placebo (+MTX)  vs 
abatacept (10mg/kg 
q4w) 
2002-2004 393 305 
(78.0) 
53.1 
(11.9) 
11.8 (8.7) 24 LOCF SF36 42.1 
(12.2) 
ATTEST Meta-analysis Placebo (+MTX) vs 
abatacept (10mg/kg)  
Placebo vs infliximab 
(3mg/kg) 
- 431 362 
(84.0) 
49.2 
(12.0) 
 28 LOCF SF36 - 
ATTRACT Narrative 
Synthesis 
Placebo (+MTX) vs 
infliximab (3mg/kg 
q8w-10mg/kg q4w 
1997-1998 428 332 
(78.0) 
54 10.6 (8.4) 102 - SF36 Median 
= 48.1 
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AVERT Meta-analysis MTX vs abatacept 
(125mg/wk) 
- 511 273 
(77.8) 
47.0 
(12.6) 
0.6 (0.5) 24, 52 Imputation SF36 41.3 
(11.2) 
BEST Narrative 
Synthesis 
Sequential 
monotherapy vs 
step-up combination 
therapy vs initial 
combination therapy 
+ prednisolone vs 
initial combination 
therapy + infliximab 
2000-2002 508 343 
(67.5) 
54.4 
(13.8) 
Median = 
0.5 
12, 24, 
52, 104 
ITT SF36 47.3 
Burmester 2013  Excluded Placebo (+MTX)  vs 
mavrilimumab 
(100mg eow) 
- 139 - - - 4, 12 - SF36 - 
CERTAIN Meta-analysis Placebo (+MTX) vs 
certolizumab 
(200mg) 
2008-2010 194 156 
(80.4) 
53.8 
(12.2) 
4.6 (3.4) 24 LOCF SF36 43.2 
(10.7) 
Choy 2012 Meta-analysis Placebo (+MTX)  vs 
certolizumab 
(400mg) 
2002-2004 247 171 
(69.2) 
54.3 
(12.0) 
9.7 (7.7) 24 LOCF SF36 45.7 
(12.3) 
COMET Meta-analysis MTX (7.5mg-
50mg/wk) vs 
etanercept 
(50mg/wk) 
2004-2006 542 387 
(73.0) 
51.4 
(13.8) 
0.8 (0.5) 52 LOCF SF36, HADS SF36: 
42.2 
(12.0) 
HADS 
(dep): 
6.8 
(4.1)   
HADS 
(anx): 
7.5 
(4.4) 
CONCERTO Narrative 
Synthesis 
MTX 
(2.5mg/5mg/10mg/20
mg) vs adalimumab 
(40mg eow) 
2010-2012 395 300 
(75.9) 
51.9 
(13.4) 
0.3 (0.4) 26 LOCF SF36 - 
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Damjanov 2016 Meta-analysis SBI-087 (200mg) + 
MTX vs placebo 
(+MTX)   
- 209 164 
(78.5) 
54.7 
(12.2) 
8.5 (7.8) 16, 24 LOCF SF36 - 
DANCER Meta-analysis Placebo (+MTX)   vs 
rituximab (2x500mg)     
Placebo (+MTX)   vs 
rituximab 
(2x1000mg) 
- 367 287 
(78.2) 
51.4 
(11.6) 
10.7 (8.2) 24 Excluded SF36 41.4 
(12.0) 
Durez 2004 Meta-analysis Infliximab (3mg/kg) 
(+MTX)  vs 
methylprednisolone 
(1g) (+MTX)   
- 27 23 
(85.2) 
Median 
=42.0 
Median 
=11.0 
14 - SF36 48.5 
Emery 2006 Meta-analysis Placebo (+MTX)  vs 
abatacept (10mg/kg)   
Placebo (+MTX)  vs 
abatacept (2mg/kg) 
- 339 230 
(68.0) 
55 9.4 (8.7) 52 LOCF SF36 43.8 
(12.7) 
FAST4WARD Meta-analysis Placebo vs 
certolizumab 
(400mg) 
2003-2004 220 184 
(83.6) 
53.8 
(12.2) 
9.6 (8.9) 24 Imputation SF36 44.7 
(11.5) 
FUNCTION Meta-analysis Placebo (+MTX) vs 
tocilizumab 
(4mg/kg)+MTX 
Placebo (+MTX) vs 
tocilizumab 
(8mg/kg)+MTX   
Placebo  (+MTX) vs 
tocilizumab (8mg/kg) 
- 1157 904 
(78.1) 
50.1 
(13.5) 
0.5 (0.5) 24, 52 Excluded SF36 - 
Genovese 2004  Excluded Etanercept (25mg 
biw) (+MTX) vs 
etanercept (25mg 
biw) + anakinra 
(100mg qd) (+MTX)                                     
Etanercept (25mg 
biw) (+MTX)  vs 
etanercept (25mg 
qw) + anakinra 
(100mg qd) (+MTX) 
- 242 187 
(77.3) 
54.6 
(12.8) 
9.9 (9.8) 24 ITT SF36 46.4 
(11.7) 
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GO-FORWARD Meta-analysis Placebo (+MTX) vs 
golimumab (100mg)      
Placebo (+MTX) vs 
golimumab (50mg)          
Placebo (+MTX) vs 
golimumab 
(100mg)+MTX 
2005-2007 444 358 
(80.6) 
50.4 
(11.3) 
8.3 (8.0) 24 ITT SF36 43.8 
(11.0) 
GO-FURTHER Meta-analysis Placebo (+MTX) vs 
golimumab (2mg/kg) 
2009-2011 592 483 
(81.6) 
51.8 
(12.1) 
7.0 (7.1) 24 LOCF SF36 37.6 
(11.3) 
HERA Meta-analysis HD203 (25mg biw) 
vs etanercept (25mg 
biw) (+MTX) 
2010-2012 294 202 
(68.7) 
51.2 
(12.2) 
7.7 (7.4) 24, 48 LOCF SF36 39.8 
(11.6) 
HIKARI Meta-analysis Placebo (+MTX) vs 
certolizumab 
(200mg) 
2008-2010 230 171 
(74.3) 
55.7 
(10.0) 
5.6 (4.2) 12, 24 LOCF SF36 44.8 
(12.9) 
HIT HARD Meta-analysis Placebo (+MTX) vs 
adalimumab (40mg 
eow) 
2007-2010 172 118 
(68.6) 
49.9 
(13.2) 
0.1 (0.7) 24, 48 MI SF36 46.0 
(10.1) 
IMAGE Meta-analysis Placebo (+MTX) vs 
rituximab (2x500mg)     
Placebo (+MTX) vs 
rituximab 
(2x1000mg) 
2006-2007 748 607 
(81.1) 
48.0 
(13.1) 
0.9 (1.2) 52 LOCF SF36 36.7 
(12.2) 
J-RAPID Meta-analysis Placebo (+MTX) vs 
certolizumab 
(400mg)            
Placebo (+MTX) vs 
certolizumab 
(200mg)             
Placebo (+MTX) vs 
certolizumab 
(100mg) 
2008-2010 316 262 
(82.9) 
53.1 
(10.9) 
5.9 (4.1) 24 LOCF SF36 46.6 
(11.7) 
Keystone 2004 Narrative 
Synthesis 
Placebo (+MTX) vs 
adalimumab (40mg 
biw)                
Placebo (+MTX) vs 
adalimumab (20mg 
biw) 
- 619 464 
(75.0) 
56.5 
(12.0) 
11.0 (9.1) 12, 24, 
52 
ITT SF36 - 
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Kim 2013 Excluded Placebo (+MTX) vs 
infliximab (3mg/kg) 
2005-2006 143 128 
(89.5) 
50.4 
(10.8) 
Median 
=8.6 
30 ITT SF36 - 
Kremer 2003 Narrative 
Synthesis 
Placebo (+MTX) vs 
abatacept (2mg/kg 
q4w)                 
Placebo (+MTX) vs 
abatacept (10mg/kg 
q4w) 
2000-2001 339 231 
(68.1) 
55 9.4 (8.7) 24 LOCF SF36 43.2 
(10.8) 
Kremer 2014 Excluded Placebo (+MTX) vs 
mavrilimumab (30-
100mg eow) 
- 326 282 
(86.5) 
51.8 
(11.1) 
- 12, 24 ITT SF36 - 
Li 2016 Meta-analysis Placebo (+MTX) vs 
golimumab (50mg 
q4wks) 
- 264 214 
(81.1) 
47.2 
(11.8) 
7.8 (7.2) 24 LOCF SF36 39.6 
(11.1) 
Machado 2014 Meta-analysis DMARD+MTX 
(7.5mg-25mg/wk) vs 
etanercept 
(50mg/wk)+MTX 
(7.5mg-25mg/wk) 
2009-2012 423 376 
(88.8) 
48.5 
(11.7) 
8.5 (7.3) 24 LOCF SF36 SF36: 
40.0 
(10.7)  
Manders 2015 Excluded Anti-TNF vs 
abatacept (10mg/kg 
q4w)                     
Anti-TNF vs 
rituximab (1000mg 
eow) 
2009-2012 144 104 
(74.8) 
56.3 
(11.2) 
Median = 
6.3 
24, 52 ITT SF36 - 
Mathias 2000 Meta-analysis Placebo vs 
etanercept (25mg 
biw)                
Placebo vs 
etanercept (10mg 
biw) 
- 234 182 
(77.9) 
52.3 12 2, 12, 24 LOCF SF36 41.7 
Mease 2012 Meta-analysis Placebo (+MTX) vs 
clazakizumab (80-
320mg) 
2008-2009 127 - 52.5 
(11.3) 
7.0 (6.0) 16 ITT SF36 34.5 
(11.9) 
MUSICA Narrative 
Synthesis 
MTX 
(7.5mg/wk)+adalimu
mab (40mg eow) vs 
MTX 
- 309 - 54.8 - 24 LOCF SF36 - 
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(20mg/wk)+adalimu
mab (40mg eow) 
OPERA Meta-analysis Placebo (+MTX) vs 
adalimumab (40mg 
eow) 
2007-2009 180 119 
(66.1) 
55.2 0.2 52 LOCF SF36 46.9 
OPTION Meta-analysis Placebo (+MTX) vs 
tocilizumab (4mg/kg) 
Placebo (+MTX) vs 
tocilizumab (8mg/kg) 
2005-2006 623 510 
(81.9) 
50.9 
(12.2) 
7.6 (7.3) 24 Excluded SF36 40.0 
(11.1) 
ORAL Meta-analysis Placebo (+MTX) vs 
tofacitinib (5/10mg 
bid) 
2009-2011 399 335 
(84.0) 
55.0 
(11.4) 
12.3 24 ITT SF36 42.5 
(12.9) 
ORAL-SCAN Meta-analysis Placebo (+MTX) vs 
tofacitinib (5/10mg 
bid) 
2009-2011 797 679 
(85.2) 
52.8 
(11.6) 
9.1 4, 12, 
24, 52 
Excluded SF36 42.1 
(11.6) 
ORAL-
STANDARD 
Meta-analysis Placebo (+MTX) vs 
tofacitinib (5/10mg 
bid)                    
Placebo (+MTX) vs 
adalimumab (40mg 
eow) 
2009-2011 717 586 
(81.7) 
53.2 
(12.6) 
7.8 24 Excluded SF36 41.0 
(11.3) 
ORAL-START  Meta-analysis MTX (10mg-
20mg/wk) vs 
tofacitinib (5/10mg 
bid) 
2010-2013 956 758 
(79.3) 
49.5 3 52, 104 Excluded SF36 - 
ORBIT Meta-analysis MTX + rituximab 
(2x500mg) vs MTX + 
anti-TNF 
(adalimumab 40mg 
eow or etanercept 
50mg pw) 
2009-2013 295 213 
(72.2) 
57.0 
(10.0) 
7.4 (7.3) 52 ITT HADS - 
PLANETRA Meta-analysis Infliximab (3mg/kg) 
vs biosimilar (CT-
P13 3mg/kg) 
- 506 501 
(82.7) 
Median = 
50 Range 
18-75 
- 14, 30, 
54 
LOCF SF36 37.6 
(10.9) 
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PREMIER Meta-analysis MTX (20mg/wk) vs 
adalimumab (40mg 
eow) vs adalimumb 
(40mg eow) + MTX 
(20mg/wk) 
- 799 595 
(74.5) 
52.0 
(13.5) 
0.7 (0.8) 12, 26, 
52, 76, 
104 
- SF36 43.4 
(12.3) 
PRIZE Meta-analysis Placebo (+MTX) vs 
MTX (10-25mg/wk) 
vs etanercept (25mg) 
+MTX 
2009-2012 193 125 
(64.8) 
49.4 
(14.4) 
0.3 (0.2) 39 LOCF SF36 43.5 
(10.8) 
RA-BEACON Meta-analysis Placebo (+DMARD) 
vs MTX + baricitinib 
(2mg or 4mg daily) 
2013-2014 527 431 
(81.8) 
55.7 
(11.0) 
14.0 (9.0) 24 ITT SF36 - 
RA-BEAM  Meta-analysis Placebo (+MTX) vs 
baricitinib (4mg QD) 
vs adalimumab 
(40mg q2w) 
2012-2014 1305 1008 
(77.2) 
53.3 (5.3) 10.0 (9.0) 24 LOCF SF36 - 
RADIATE Meta-analysis Placebo (+MTX) vs 
tocilizumab 
(4mg/kg)+MTX 
Placebo (+MTX) vs 
tocilizumab 
(8mg/kg)+MTX 
- 499 398 
(79.8) 
52.7 
(12.8) 
11.7 (9.0) 24 Excluded SF36 41.1 
(11.9) 
RA-MOBILITY  Meta-analysis Placebo (+MTX) vs 
sarilumab (150mg 
q2w)                   
Placebo (+MTX) vs 
sarilumab (200mg 
q2w) 
- 1197 982 
(82.0) 
50.6 
(11.6) 
9.1 52 ITT SF36 38.9 
(11.6) 
RAPID1 Meta-analysis Placebo (+MTX) vs 
certolizumab 
(400mg)            
Placebo (+MTX) vs 
certolizumab 
(200mg) 
2005-2006 982 817 
(83.2) 
52.0 
(11.5) 
6.2 (4.3) 12, 24, 
52 
LOCF SF36 39.3 
(11.2) 
RAPID2 Meta-analysis Placebo (+MTX) vs 
certolizumab 
(400mg)            
Placebo (+MTX) vs 
2005-2006 619 505 
(81.6) 
51.9 
(11.6) 
6.1 (4.1) 24 LOCF SF36 39.4 
(11.1) 
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certolizumab 
(200mg) 
REFLEX Meta-analysis Placebo (+MTX) vs 
rituximab 
(2x1000mg) 
- 520 420 
(80.8) 
52.5 
(12.4) 
11.9 (8.0) 24 LOCF SF36 39.9 
(11.4) 
SERENE Meta-analysis Placebo (+MTX) vs 
rituximab (2x500mg)     
Placebo (+MTX) vs 
rituximab 
(2x1000mg) 
- 511 418 
(81.8) 
51.8 
(12.7) 
7.1 (7.3) 24 Excluded SF36 41.2 
(11.9) 
SIRROUND-D Meta-analysis Placebo (+MTX) vs 
sirukumab (50mg 
q2w or 100mg q4w) 
2012-2016 1670 - - - 24 ITT SF36 - 
SIRROUND-T Meta-analysis Placebo (+MTX) vs 
sirukumab (50mg 
q2w or 100mg q4w) 
2012-2016 878 712 
(81.0) 
55.4 
(12.2) 
12.5 (8.9) 24 ITT SF36 - 
Smolen 2012 Meta-analysis Placebo (+MTX) vs 
baricitinib (1mg-8mg) 
- 301 - - - 12 - SF36 - 
Smolen 2014a Meta-analysis Placebo (+MTX)  vs 
sirukumab (100mg 
eow) 
2008-2011 36 25 
(69.4) 
48.2 (7.0) 7.4 (6.8) 12 LOCF SF36 37.4 
(11.3) 
Smolen 2014b Meta-analysis Placebo (+MTX) vs 
sirukumab (25-
200mg q4w) 
2008-2011 151 133 
(88.1) 
52.7 
(11.3) 
10.0 (7.5) 12 LOCF SF36 37.2 
(11.3) 
St Clair 2004 Excluded Placebo (+MTX)  vs 
infliximab (3mg/kg)                
Placebo (+MTX) vs 
infliximab (6mg/kg) 
2000-2002 1004 713 
(71.0) 
50.3 
(12.7) 
0.9 (0.7) 54 LOCF SF36 - 
START Excluded Placebo (+MTX) vs 
infliximab (10mg/kg)   
Placebo (+MTX) vs 
infliximab (3mg/kg) 
2001-2003 1084 871 
(80.4) 
52.3 7.5 22 LOCF SF36 45.1 
Strand 2011 Meta-analysis Placebo (+MTX) vs 
tofacitinib (5/10mg 
bid) 
- 792 - - - 24 Excluded SF36 41.4 
(11.8) 
Strand 2012 Narrative 
Synthesis 
Placebo vs 
secukinumab  (25-
300mg q4w) 
- 237 - - - 2, 4, 8, 
12, 16 
- SF36 - 
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Strand 2013 Meta-analysis Placebo vs 
decernotinib   (25-
150mg bid) 
- 204 - 56.2 (9.9) 7.7 12 Imputation SF36 39.0 
(11.7) 
TACIT Meta-analysis cDMARD strategy vs 
tumour necrosis 
factor inhibitor 
strategy  
2008-2010 214 144 
(67.3) 
57.5 
(12.0) 
Median = 
5.2 Range 
= 1.6-13.4 
52 MI SF36 42.0 
(12.0) 
TASKi-2 Meta-analysis Placebo (+MTX) vs 
fostamatinib (100mg 
bid)                        
Placebo (+MTX) vs 
fostamatinib 
(150mg/day) 
- 457 390 
(85.3) 
52.5 
(12.8) 
9.2 (8.7) 24 ITT SF36 40.3 
(11.6) 
TOWARD Meta-analysis Placebo (+MTX) vs 
tocilizumab (8mg/kg) 
2005-2007 1220 997 
(81.7) 
53.5 
(13.0) 
9.8 (9.0) 24 ITT SF36 - 
Westhovens 
2009 
Meta-analysis Placebo (+MTX) vs 
abatacept (10mg/kg 
q4w) 
- 509 395 
(77.6) 
49.9 
(12.7) 
0.5 (0.6) 52 LOCF SF36 - 
QD once per day. Q4w every 4 weeks. Eow every other week. Wk week. Q8w every 8 weeks. Biw twice a week. Bid twice a day. LOCF Last Observation Carried 
Forward. ITT Intention to Treat. MTX methotrexate 
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Figure 1. Flow diagram of systematic literature search
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Objective 2: The impact of RA treatment on mental health 
Results of the PMA, sensitivity and subgroup analyses are shown in table 2. The total analysis 
involving 57 studies, with no exclusions and all comparators, revealed a statistically significant 
but modest effect of all treatments on mental HRQoL (MCS) (SMD=0.21). This indicates that, 
on average, bDMARDs were related to a treatment effect, compared to control treatments, of 
around one-fifth of a standard deviation, which is equivalent to around a two point difference 
in MCS units. In comparison, the impact of RA treatments on physical HRQoL (PCS) is 
somewhat larger (SMD= 0.41) and equivalent to a difference of around four points on the PCS 
scale. I2 values reflected moderate-high levels of heterogeneity for both PCS (I2=76.5) and 
MCS (I2=59.2) outcomes. This suggests that estimates may not be robust as an indicator of 
the population average effect; potentially due to moderating factors, such as differences in 
trial design. 
When limiting the analysis to no-treatment placebo controls, bDMARDs had a substantial 
benefit for PCS but not MCS outcomes (SMDs = .52 versus .27, respectively). Comparisons 
with csDMARD controls did not significantly alter the findings from the total analysis (SMDs = 
.47 versus .24, respectively). For both analyses, heterogeneity levels were reduced compared 
to the any comparator analysis but remained moderate (>40%) for both MCS and PCS 
outcomes. Subgroup analysis of unpublished data provided by authors and funders revealed 
little difference in impact of bDMARDs on MCS and PCS in comparison to background 
csDMARD control groups compared to all trials. 
csDMARDs (typically MTX) was a common comparator against which all bDMARDs had been 
assessed (see network of comparisons in appendix 5). NMA results for bDMARDs versus 
csDMARDs are shown in figure 3. These demonstrated consistently small effect sizes for MCS 
and moderate effects for PCS outcomes. All bDMARDs performed better than csDMARDs for 
improving MCS and PCS outcomes, although there were no notable differences in outcomes 
between mode of bDMARD action. Effect sizes for MCS outcomes were typically 50% smaller 
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than PCS effect sizes. Figure 2 shows the comparator-adjusted funnel plot for the NMA MCS 
outcome analysis, demonstrating no substantial publication bias.  
SUCRA rankings (figure 3) show that for MCS outcomes, out of the drugs considered in the 
analysis, biologics targeting anti-IL-6 have an 90% probability of being the most effective 
treatment for MCS outcome; abatacept has an 83% probability of most effectively improving 
PCS outcomes.  
 
 
 
 
Figure 2. Comparator-adjusted funnel-plot for MCS outcomes 
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Table 2. Pairwise meta-analysis results with sensitivity and subgroup analysis. 
Analysis Outcome Number of 
studies 
Number of 
comparisons 
Number of 
participants 
SMD (95% CI) p-value I2 statistic 
(%) 
bDMARD vs any comparator* SF36 MCS 57 67 23,535 0.21 (0.17, 0.25) <0.001 59.2 
 SF36 PCS 55 65 23,108 0.41 (0.35, 0.47) <0.001 76.5 
bDMARD vs no-treatment 
placebo 
SF36 MCS 7 7 2,700 0.27 (0.16, 0.38) <0.001 41.6 
 SF36 PCS 6 6 2,542 0.52 (0.40, 0.64) <0.001 41.3 
bDMARD vs csDMARD SF36 MCS 44 47 16,678 0.24 (0.19, 0.29) <0.001 52.9 
 SF36 PCS 44 47 16,678 0.47 (0.42, 0.52) <0.001 57.4 
bDMARD vs csDMARD 
(unpublished)** 
SF36 MCS 10 12 3,352 0.22 (0.12, 0.32) <0.001 46.2 
 SF36 PCS 10 12 3,352 0.45 (0.35, 0.55) <0.001 38.4 
bDMARD targeted disease modifying anti-rheumatic drug. csDMARD conventional synthetic disease modifying anti-rheumatic drug. PCS = physical component summary 
scores (physical quality-of life). MCS = mental component summary scores (mental quality-of life). SMD Standardised Mean Difference. CI = Confidence Intervals. 
*placebo/csDMARD/steroid/bDMARD **Unpublished data supplied by author/funder.  
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Objective 3: Variables associated with the impact of RA treatment on mood 
outcomes.  
The results of the meta-regression analyses, including studies to background csDMARD 
comparators, are provided in Table 3. These results show that sample size, age, proportion 
female, baseline levels of MH, disease activity, rheumatoid factor (RF) status, year of 
recruitment and availability of baseline data were not associated with variability in the 
treatment effect sizes in the PMA results for MCS or PCS outcomes. There was a small but 
significant positive association between disease duration and MCS outcomes and number of 
follow-up weeks and PCS outcomes. This indicates that every increased year of disease 
duration is associated with a 0.04 increase in MCS effect size (i.e. a reduction in treatment 
efficacy), and every increased week of follow-up time is associated with an increase of 0.01 
in PCS effect size.  
Risk of bias 
The GRADE assessment suggested that the MCS and PCS outcome PMA of bDMARD versus 
csDMARDs were of moderate quality. Whilst there was no serious indirectness, imprecision 
or publication bias, few studies were completely without risk of bias and there was moderate 
heterogeneity. A full summary of the risk of bias assessment is provided in appendix 4. 
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Figure 3. Estimated pooled treatment effects of biologics therapies on PCS and MCS outcomes. *Total bDAMRD 
versus csDMARDs pairwise analysis. 
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Table 3. Meta-regression of moderators of the impact of RA treatment on MCS and PCS outcomes. 
MCS Comparison N Study N Participant N SMD (95%CI) p value  I2 Statistic (%) 
Comparison analysis:                                  
Total versus background DMARD control 
44 47 16,678 0.24 (0.19, 0.29) <0.0001 52.9 
Covariates Beta SE Lower CI Upper CI  p value R-Squared (%) 
Age (continuous) 0.01 0.01 -0.01 0.03 0.244 0.31 
Proportion female (continuous) 0.01 0.01 -0.01 0.03 0.683 -0.06 
Disease duration (years, continuous) 0.04 0.02 0.00 0.07 0.038 2.83 
Early RA (versus established RA)* -0.28 0.16 -0.61 0.04 0.084 1.68 
MCS at baseline (continuous) -0.03 0.03 -0.08 0.03 0.324 0.04 
DAS28 at baseline (continuous) 0.04 0.16 -0.28 0.35 0.806 -0.86 
Follow-up time (weeks, continuous) 0.01 0.00 -0.00 0.01 0.056 1.94 
Percentage RF positive 0.00 0.01 -0.02 0.02 0.872 -0.89 
Year of recruitment start 0.05 0.04 -0.03 0.12 0.213 0.86 
Unpublished (versus published) 0.11 0.17 -0.23 0.46 0.519 4.12 
PCS Comparison N Study N Participant N SMD (95%CI) p value  I2 Statistic (%) 
Comparison analysis: 
Total versus background DMARD control 
44 47 16,678 0.47 (0.42, 0.52) <0.0001 57.4 
Covariates Beta SE Lower CI Upper CI  p value R-Squared (%) 
Age (continuous) 0.01 0.01 -0.01 0.03 0.356 -0.09 
Proportion female (continuous) 0.00 0.02 -0.03 0.03 0.986 -0.82 
Disease duration (years, continuous) 0.04 0.02 -0.00 0.09 0.066 2.22 
Early RA (versus established RA)* -0.22 0.20 -0.61 0.16 0.250 0.34 
MCS at baseline (continuous) -0.03 0.03 -0.09 0.04 0.373 -0.12 
DAS28 at baseline (continuous) 0.06 0.19 -0.31 0.44 0.735 -0.84 
Follow-up time (weeks, continuous) 0.01 0.00 -0.00 0.01 0.045 2.27 
Percentage RF positive -0.01 0.01 -0.03 0.02 0.535 -0.73 
Year of recruitment start 0.07 0.05 -0.02 0.16 0.129 1.82 
Unpublished data (versus published) 0.11 0.22 -0.32 0.54 0.628 6.72 
MCS Mental Component Summary. PCS Physical Component Summary. DAS28 28-joint Disease Activity Score. RF Rheumatoid Factor. SMD Standardised Mean Difference. CI 
Confidence Interval. *Early RA defined as overall study mean disease duration <3 years 
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DISCUSSION 
Despite MH problems being highly prevalent, [3] predictive of worse disease outcomes and 
treatment response, [8,33] and being highlighted as a priority for outcome measurement by 
patients, [34,35] 74 (51.0%) of 145 otherwise eligible trials did not measure MH and were 
excluded from this systematic review. Of the 71 eligible studies indicating that MH had been 
measured, 35 (49.3%) did not report treatment effect estimates. The results of PMA of 57 trials 
of targeted treatment show a relatively small but significant impact of bDMARDs on MH 
assessed by the SF36. The impact of targeted RA treatment on SF36-MCS was approximately 
half the effect seen in SF36-PCS. The largest effect size for MCS outcomes was 0.30, found 
for the anti-IL-6 versus csDMARD comparison; the lowest effect size was 0.19, found in the 
Kinase inhibitors.  
To date, TNFα has been the primary focus of research investigating the inflammatory 
mechanisms involved in the presence of depressive symptomatology. Infliximab has been 
recently investigated as an anti-depressant in treatment-resistant depression, [14] and the 
impact of anti-TNF medications on depression outcomes in chronic physical conditions has 
been addressed in a recent systematic review and meta-analysis of six trials. [15] Building on 
this review, [15] we focused only on RA, but included broader conceptualisations of MH and 
more treatment types. By including treatments with varied modes of action, we hoped to 
pinpoint the mechanism through which RA treatment may have benefits for MH. However, we 
failed to find any major variations between treatment modes of action. Whilst we found one of 
the largest effects on MH for treatments targeting IL-6, the smallest effect size was observed 
for anti-TNF treatments. Therefore, it remains largely unclear as to the extent to which 
improvements in MH are through bDMARDs directly impacting inflammatory pathways, or 
simply indirectly through the reduction in pain and disability. 
Meta-regression analysis identified a small but significant association between disease 
duration and MCS effect size, and the largest (although non-significant) R-squared value for 
comparing data which had been published online versus unpublished data which was 
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requested from authors. Although we found no clear evidence of publication bias in our funnel 
plots, there may be a tendency for non-significant mental health outcomes to be omitted from 
published papers. [36] 
This review used reproducible and rigorous methods to collate and synthesize the data in this 
field. We included many trials, representing >20,000 patients, and study quality was relatively 
high. There are some restrictions which limit the interpretation of our results. We used broad 
inclusion criteria for the entry of studies into this review, preferring to use sensitivity and 
subgroup analyses and meta-regression to examine sources of statistical heterogeneity in the 
PMA, which was substantial. In addition to heterogeneity due to the different types of 
bDMARDs included, heterogeneity may also be explained by the comparator used, plus 
variability in disease duration and length of follow-up between studies. Another, source of 
heterogeneity may be that we did not restrict our focus to trials specifically recruiting patients 
with low mood at baseline. The overall mean MCS score at baseline was 42.2, with 20.8% of 
studies reporting a mean MCS score reaching below a threshold of 40, indicated as a 
threshold for possible mood disorder. [37] Most patients included in the studies may not have 
had mood disorder at baseline, restricting potential to find an ‘anti-depressant’ effect.  
NMA methodologies are being more widely used in medical research, however there are 
limitations to the technique which need addressing. Firstly, it is important to highlight that, as 
treatment allocations have been randomised within (not between) trials, NMA can only provide 
observational evidence [38].  NMA assumes transitivity (whether any patient could be given 
any treatment in the network) and consistency (similar estimates obtained from direct and 
indirect comparisons). Our focus on bDMARDS, which are relatively recently developed, 
typically involve similar inclusion criteria, and generally are considered to be equally 
efficacious [39], limits the potential for violation of the transitivity assumption. Regarding the 
consistency assumption, examining loop specific heterogeneity we found no specific cause 
for concern.   
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Despite not limiting our search strategy to the SF36, we identified the SF36 as the most 
commonly-used tool for measuring mental health, and data from this were prioritised to allow 
meaningful comparison across studies. Whilst this measure allows interesting comparison 
between mental and physical QoL outcomes, it is important to acknowledge that the SF36 
MCS captures a broader conceptualisation of mental health-related quality of life. This 
includes symptoms of depression and anxiety but also vitality/fatigue and impacts on social 
and emotional functioning. [24] Future research may benefit from identifying subgroups of 
patients who may be susceptible to experiencing MH benefits following RA treatments and 
understanding how these patients may differ from those who are more resistant to 
improvement. This may provide useful clinical information to anticipate treatment response, 
as improvement in MH in turn is likely to further impact physical symptom experiences [33]. 
This approach may also identify potentially useful intervention targets.  A focus on RA patients 
with symptoms of MH at baseline may provide insight into any benefits of RA treatment on a 
subgroup of people with both heightened inflammation and psychological disorder. 
Conclusion 
Advances in RA treatment have resulted in significant improvements in specific outcomes: the 
delay of radiographic damage and reduction of inflammation and adverse events. [40] 
However this review demonstrates that relying on RA pharmacotherapy alone may not 
meaningfully improve MH outcomes. MH is treatable in patients with physical illness, [41,42] 
and the measurement and management of MH throughout the course of treatment as part of 
routine practice is recommended. [43] Our results suggest that MH in patients with RA must 
be addressed and are unlikely to resolve with effective RA pharmacological disease 
management alone. Providing integrated, dedicated MH care within routine practice is 
essential to achieve parity of esteem, valuing mental and physical health equally.  
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